AbbVie拍打收入估计数,提出2026年的指导意见,并报告了新药品的试验结果,尽管付款比率和营业机构销售额都很高。 AbbVie beat earnings estimates, raised 2026 guidance, and reported positive trial results for new drugs, despite high payout ratio and institutional selling.

AbbVie报告说,2025年Q4收入强劲,有2.71 EPS和166.2亿美元的收入,超过估计数,并显示年增长率为10%。 AbbVie reported strong Q4 2025 earnings with $2.71 EPS and $16.62 billion in revenue, surpassing estimates and showing 10% year-over-year growth. 该公司提出了其2026年全年EPS指南,并宣布ABBV-295第1阶段取得积极结果,这是一种潜在的肥胖治疗,SKYRIZI在克罗恩病中取得了第3阶段的成功。 The company raised its 2026 full-year EPS guidance and announced positive Phase 1 results for ABBV-295, a potential obesity treatment, and Phase 3 success for SKYRIZI in Crohn’s disease. 尽管Capital International和Capital Group私人客户服务公司进行了机构销售,但分析师的情绪基本保持积极,J.P.Morgan坚持购买评级。 Despite institutional selling by Capital International and Capital Group Private Client Services, analyst sentiment remains largely positive, with J.P. Morgan maintaining a Buy rating. AbbVie宣布季度红利为1.73美元,收益率为3.0%,尽管其付款比率高达293.22%。 AbbVie declared a $1.73 quarterly dividend, yielding 3.0%, though its payout ratio is high at 293.22%. 股票交易的市场上限为4 027亿美元,P/E为96.50美元。 The stock trades at a market cap of $402.7 billion with a P/E of 96.50.